Cargando…
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
Autores principales: | Caocci, Giovanni, La Nasa, Giorgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220809/ https://www.ncbi.nlm.nih.gov/pubmed/32405693 http://dx.doi.org/10.1007/s00277-020-04067-6 |
Ejemplares similares
-
Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016) -
COVID-19-associated acute respiratory distress syndrome (C-ARDS): Inhaled nitroglycerin could be an efficient pulmonary vasodilator
por: Daunaria, Deepak K., et al.
Publicado: (2023) -
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis
por: Caocci, Giovanni, et al.
Publicado: (2021) -
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
por: Neubauer, Andreas, et al.
Publicado: (2020) -
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
por: Neubauer, Andreas, et al.
Publicado: (2021)